Pregnancy (Hoboken). 2026 Nov 14;2(6):e70500. doi: 10.1002/pmf2.70500. eCollection 2026 Nov.
ABSTRACT
BACKGROUND: Dapagliflozin (DAPA), a sodium-glucose co-transporter inhibitor (SGLT2i), has been shown to prevent the development of heart failure and slow the progression of pre-existing heart failure; however, there are limited data published to demonstrate the safety of postpartum lactating individuals taking SGLT2is.
METHODS: Lactating patients received two oral doses of 10 mg DAPA over a 48-h period. Breast milk and plasma were collected 2 h after the second dose. Samples were processed via liquid chromatography mass spectrometry (LCMS) analysis. Breast milk concentrations of DAPA were divided by plasma concentrations of DAPA (in ng/mL). The absolute (AID; i.e., daily infant dose) and relative infant doses (RID) were performed. An RID of 10% was considered the limit of acceptable exposure.
RESULTS: Three of four participants were able to produce enough sample for assessment. Across three samples, the mean DAPA concentrations in plasma and breast milk were 77.6 ± 10.2 and 16.8 ± 3.1 ng/mL, respectively. Mean AID was 8.04 × 10-3 ± 2.50 × 10-3 mg/day and the mean RID was 7.73 ± 3.9%.
CONCLUSIONS: This study demonstrates that human breast milk collected at peak anticipated maternal concentrations of DAPA has a mean RID below 10%. This is the first report of human transfer levels for DAPA, generating preliminary lactation-specific pharmacokinetic data that are essential to support evidence-based treatment of breastfeeding individuals and reduce disparities in their representation within cardiovascular therapeutic research.
PMID:43034521 | PMC:PMC13769040 | DOI:10.1002/pmf2.70500

